VEGFA and hepatocellular carcinoma: Genetic alterations, such as single nucleotide polymorphisms (SNPs) in genes encoding proteins involved in the angiogenic process, have been studied as potential biomarkers for antiangiogenic therapy, and specific SNPs in the VEGF and VEGF receptor genes were associated with PFS and OS in HCC patients treated with sorafenib [25].